Recent research into retatruptide peptide highlight promising possibility for treating excess body and non-insulin dependent disease. The compound, a dual agonist of GLP-1 receptor and GIP, appears to offer improved weight reduction and blood sugar regulation compared existing medications. Further patient studies are necessary to fully evaluate its